Limb-girdle muscular dystrophy type 2B (LGMD 2B) is a hereditary disorder characterized by progressive weakening of skeletal muscles, which predominantly affects the muscles of the extremities and lumbar region. The disease is associated with mutations in the genes encoding proteins necessary for the normal functioning of muscle fibers. LGMD 2B usually manifests itself in childhood or adolescence and can lead to significant physical limitations, reduced quality of life, and complications such as scoliosis and contractures. The pathology can also affect the cardiovascular system, which requires special medical supervision and rehabilitation.
History of the disease and interesting historical facts
Limb-girdle muscular dystrophy was first described in the mid-20th century by pediatricians and geneticists who observed the clinical manifestations of this pathology in children. In the 1960s, the main clinical characteristics were identified, which allowed a more systematic study of the disease to begin. It is important to note that the disease was initially considered rare, but with the development of research in the field of genetics and neurology, it was found that many cases remain unnoticed due to insufficient awareness of the medical community and parents. The discovery of mutations in the DMD and UBA1 genes involved in the pathogenesis of the disease opened up new horizons for the diagnosis and treatment of limb-girdle muscular dystrophy 2B.
Epidemiology
According to current research, the prevalence of limb-girdle muscular dystrophy is approximately 1 in 50,000 live births. However, given the difficulties in diagnosis and certain cases that remain without medical attention, the actual prevalence may be higher. The disease is observed significantly more often in males than in females, which can be explained by the recessive type of inheritance associated with the sex chromosome. To obtain accurate data, multicenter studies are being conducted that collect information on cases of limb-girdle muscular dystrophy worldwide.
Genetic predisposition to this disease
CMMD 2B is caused by mutations in genes responsible for the synthesis of proteins necessary for maintaining the structure and function of muscle fibers. The most significant genes involved in this disease include the DMD (dystrophin) gene and UBA1. At least 80% cases of the disease have been correlated with mutations in these genes. Mutations can occur as point changes, deletions or insertions, resulting in impaired synthesis of dystrophin, which plays a key role in maintaining the integrity of the muscle cell membrane. Genetic testing allows not only to confirm the diagnosis, but also to pre-distribution in families with a history of the disease.
Risk factors for the development of this disease
KPMD 2B has a strong genetic predisposition, but there are other factors that can increase the risk of the disease. The main risk factors include:
- Heredity – the presence of cases of the disease in the family.
- Gender – men get sick much more often.
- Associated genetic diseases, such as syndromes associated with muscular dystrophies.
- Age – diseases usually appear in childhood.
- Environmental factors such as exposure to toxic substances during pregnancy.
Diagnosis of this disease
To diagnose CMMD 2B, a comprehensive approach is required, which includes both clinical and laboratory tests. The main symptoms of the disease are:
- Progressive weakening of the muscles of the limbs.
- Gait and balance disorders.
- Scoliosis and joint contractures.
- Thinning during physical activity.
Laboratory tests may include:
- Measurement of the level of creatine kinase (CK) in the blood, which in the Czech Republic is high.
- Genetic testing to determine the presence of mutations in specific genes.
Radiologic examinations are also useful to identify associated disorders, including magnetic resonance imaging (MRI) to evaluate muscle and joint structure. Differential diagnosis includes ruling out other muscular dystrophies and nervous system disorders.
Treatment
Treatment of CPMD 2B is complex and aimed at slowing the progression of the disease and maintaining the patient's quality of life. General treatment includes:
- Physical therapy and rehabilitation to maintain muscle function.
- Exercises to strengthen muscles and improve coordination.
Pharmacological treatment may include:
- Anti-inflammatory drugs to reduce myalgia.
- Steroids to slow the progression of the disease.
Surgery may be required to correct scoliosis or contractures. Orthoses are also used to maintain proper posture and limb function.
List of medications used to treat this disease
The following medications are currently used:
- Prednisolone - to slow down muscle weakness.
- Ibuprofen – to reduce pain and inflammation.
- Creatine is a restorative drug for increasing muscle strength.
- Insulin-like growth factor-1 (IGF-1) – to improve the anatomical structure of muscle groups.
- Muscle relaxants – to reduce spasms and improve patient comfort.
Disease monitoring
Monitoring relies on regular control stages, which include:
- Clinical assessments of the patient's physical condition.
- Regular checks of heart and lung function.
- Evaluation of the effectiveness of rehabilitation measures.
- Monitoring for possible complications such as scoliosis and contractures.
The prognosis for patients with CPMD 2B varies greatly depending on the clinical presentation and early initiation of therapy. Lifestyle simplification and adjustments can help prolong active muscle function.
Age-related features of the disease
KPMD 2B has its own characteristics depending on the patient's age. In childhood, the disease can manifest itself especially actively, leading to significant physical limitations and the need for specialized therapy. In adolescents, symptoms may intensify, but temporary improvements are also possible. Adult patients face complications such as heart failure and limited mobility, which requires a comprehensive approach to treatment.
Questions and Answers
- What are the main symptoms of CMPD 2B? The main symptoms include progressive weakening of the limb muscles, gait disturbances, and possible scoliosis and contractures.
- How is this disease diagnosed? Diagnosis includes clinical symptoms, laboratory tests, genetic testing, and radiological examinations to evaluate muscle condition.
- What treatment is used for KPMD 2B? Treatment includes physical therapy, pharmacological treatment, and in some cases, surgery to correct complications.
- What is the prognosis for patients with CMMD 2B? The prognosis depends on the severity of the disease and the quality of treatment provided; proper rehabilitation can maintain motor function at a higher level.
- Is it possible to prevent the disease? Due to the hereditary nature of the disease, it cannot be completely prevented, but genetic counseling can help families at risk.
Advice from Dr. Oleg Korzhikov
It is important to remember that limb-girdle muscular dystrophy should be diagnosed and treated by specialists in this field. It is important to maintain contact with doctors, paying attention to regular examinations and following their recommendations. To reduce symptoms and improve quality of life, try to exercise regularly and improve your balanced diet. In addition, genetic counseling will help you understand the risks for future generations and make informed choices in matters of family planning.
